본문으로 건너뛰기
← 뒤로

Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.

1/5 보강
Leukemia & lymphoma 📖 저널 OA 9.2% 2022: 1/1 OA 2025: 2/55 OA 2026: 15/137 OA 2022~2026 2026 Vol.67(3) p. 536-555
Retraction 확인
출처

Bhabha F, Prince HM, Campbell B, Van Der Weyden C, Ong X, Casan J

📝 환자 설명용 한 줄

Primary cutaneous T-cell lymphomas (CTCL) are a rare and heterogeneous group, associated with significant morbidity and mortality.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Bhabha F, Prince HM, et al. (2026). Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.. Leukemia & lymphoma, 67(3), 536-555. https://doi.org/10.1080/10428194.2025.2598662
MLA Bhabha F, et al.. "Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.." Leukemia & lymphoma, vol. 67, no. 3, 2026, pp. 536-555.
PMID 41447501 ↗

Abstract

Primary cutaneous T-cell lymphomas (CTCL) are a rare and heterogeneous group, associated with significant morbidity and mortality. Mycosis fungoides (MF), the most common subtype, typically follows an indolent course, whereas Sézary syndrome (SS) is a leukemic and aggressive variant. Treatment strategies for MF are diverse, stage-dependent, and individualized to the patient. While early-stage disease can be effectively managed with skin-directed therapies, advanced or relapsed/refractory disease is associated with a poorer prognosis and frequently necessitates multiple sequential therapies. Current systemic therapeutic options include immunomodulatory drugs, targeted therapies, and chemotherapy, and are aimed at achieving disease control rather than disease cure. Presently, the only potentially curative treatment option is allogeneic stem-cell transplantation. Regional variation in drug access impacts treatment decisions, whilst the evolving landscape of novel agents continues to challenge current paradigms. This review discusses the underlying biology, clinical features, current and emerging therapeutic strategies for relapsed or refractory MF/SS.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반